<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="2003 when Savarino et al. hypothesized the possible usefulness of" exact="chloroquine" post="and hydroxychloroquine in the treatment of SARS-CoV,1 prompting several"/>
 <result pre="Savarino et al. hypothesized the possible usefulness of chloroquine and" exact="hydroxychloroquine" post="in the treatment of SARS-CoV,1 prompting several studies in"/>
 <result pre="immune system,5, 7 the combined antiviral and immunomodulatory action of" exact="hydroxychloroquine" post="makes its use pathophysiologically attractive. The first study of"/>
 <result pre="use pathophysiologically attractive. The first study of the use of" exact="chloroquine" post="in coronavirus-19 infection was conducted in China and was"/>
 <result pre="assess the effect, they measured EC50, the minimum concentration of" exact="chloroquine" post="needed to inhibit 50% of the virus, and CC50,"/>
 <result pre="harming the organism, as was seen in the case of" exact="chloroquine" post="and remdesivir.8 Since chloroquine works by preventing the entry"/>
 <result pre="was seen in the case of chloroquine and remdesivir.8 Since" exact="chloroquine" post="works by preventing the entry of the virus into"/>
 <result pre="treatment regimens were tested that verified the inhibitory potential of" exact="chloroquine" post="before and after the Vero cells infection, while remdesivir"/>
 <result pre="infection already established.8 The fact that the concentration with which" exact="chloroquine" post="managed to inhibit 90% of the pathogen, of 6.90Â"/>
 <result pre="Given this evidence, the article itself recommended the use of" exact="chloroquine" post="phosphate in patients with COVID-19,9 a recommendation which was"/>
 <result pre="On 9th March, the second in vitro clinical trial of" exact="chloroquine" post="was published, this time comparing this drug with another"/>
 <result pre="by the virus. This study revealed that the EC50 of" exact="hydroxychloroquine" post="was lower than that of chloroquine, both in therapeutic"/>
 <result pre="therapeutic and prophylactic use, which translated into greater efficacy of" exact="hydroxychloroquine" post="compared to its precursor. Likewise, the efficacy was greater"/>
 <result pre="57.1% of the patients who received 200Â daily mg of" exact="hydroxychloroquine" post="sulphate for 10 days, and 100% of those who"/>
 <result pre="days, and 100% of those who received the combination of" exact="hydroxychloroquine" post="and azithromycin, the latter at doses of 500Â mg"/>
 <result pre="of pneumonia among the group treated with 400Â mg/day of" exact="hydroxychloroquine" post="for 5 days (80.6%) compared to the control group"/>
 <result pre="and optimize the treatment offered. In addition, the use of" exact="hydroxychloroquine" post="has the incentive of its low price in relation"/>
 <result pre="efficacy and safety of the administration of 400Â mg of" exact="hydroxychloroquine" post="together with the different treatments recommended by the Chinese"/>
 <result pre="at the doses it is intended to be used because" exact="chloroquine" post="and/or hydroxychloroquine are used at high doses in the"/>
 <result pre="doses it is intended to be used because chloroquine and/or" exact="hydroxychloroquine" post="are used at high doses in the acute attack"/>
 <result pre="studies confirm that the cardiac complications reported in case of" exact="hydroxychloroquine" post="overdose, a risk that we can face with short"/>
 <result pre="Medicines.8, 12, 14 The evidence for the concomitant use of" exact="azithromycin" post="and chloroquine is more limited. Although in a 2011"/>
 <result pre="14 The evidence for the concomitant use of azithromycin and" exact="chloroquine" post="is more limited. Although in a 2011 article evaluating"/>
 <result pre="adverse events such as the presence of nausea associated with" exact="azithromycin" post="were reported,20 a recent study of 84 patients with"/>
 <result pre="a recent study of 84 patients with COVID-19 treated with" exact="hydroxychloroquine" post="and azithromycin demonstrates QTc interval prolongation, from 435Â Â±Â"/>
 <result pre="study of 84 patients with COVID-19 treated with hydroxychloroquine and" exact="azithromycin" post="demonstrates QTc interval prolongation, from 435Â Â±Â 24Â ms"/>
 <result pre="any case, a multinational study on the safety profile of" exact="hydroxychloroquine" post="alone and in combination with azithromycin is currently underway"/>
 <result pre="the safety profile of hydroxychloroquine alone and in combination with" exact="azithromycin" post="is currently underway in more than 130,000 patients with"/>
 <result pre="context in which we find ourselves, the general use of" exact="hydroxychloroquine" post="is imminent, to the extent that the availability of"/>
 <result pre="administration. Conflict of interests None declared. References References 1SavarinoA.BoelaertJ.R.CassoneA.MajoriG.CaudaR.Effects of" exact="chloroquine" post="on viral infections: an old drug against today's diseases?Lancet"/>
 <result pre="an old drug against today's diseases?Lancet Infect. Dis.3200372272710.1016/S1473-3099(03)00806-514592603 2ColsonP.RolainJ.-M.LagierJ.-C.BrouquiP.RaoultD.Chloroquine and" exact="hydroxychloroquine" post="as available weapons to fight COVID-19Int. J. Antimicrob. Agents202010593210.1016/j.ijantimicag.2020.10593232145363"/>
 <result pre="J. Antimicrob. Agents202010593210.1016/j.ijantimicag.2020.10593232145363 3DevauxC.A.RolainJ.M.ColsonP.RaoultD.New insights on the antiviral effects of" exact="chloroquine" post="against coronavirus: what to expect for COVID-19?Int. J. Antimicrob."/>
 <result pre="COVID-19?Int. J. Antimicrob. Agents202010593810.1016/j.ijantimicag.2020.10593832171740 4SahraeiZ.ShabaniM.ShokouhiS.SaffaeiA.Aminoquinolines against coronavirus disease 2019 (COVID-19):" exact="chloroquine" post="or hydroxychloroquineInt. J. Antimicrob. Agents202010594510.1016/j.ijantimicag.2020.10594532194152 5YaoX.YeF.ZhangM.CuiC.HuangB.NiuP.In vitro antiviral activity"/>
 <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
 <result pre="7ShangL.ZhaoJ.HuY.DuR.CaoB.On the use of corticosteroids for 2019-nCoV pneumoniaLancet395202068368410.1016/S0140-6736(20)30361-532122468 8WangM.CaoR.ZhangL.YangX.LiuJ.XuM.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
 <result pre="the recently emerged novel coronavirus (2019-nCoV) in vitroCell Res.30202026927110.1038/s41422-020-0282-032020029 9GaoJ.TianZ.YangX.Breakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
 <result pre="pneumonia (trial version 6)2020117Available from: http://www.gov.cn/zhengce/zhengceku/2020-02/19/content_5480948.htm 11MarmorM.F.KellnerU.LaiT.Y.Y.MellesR.B.MielerW.F.LumF.Recommendations on screening for" exact="chloroquine" post="and hydroxychloroquine retinopathy (2016 revision)Ophthalmology12320161386139410.1016/j.ophtha.2016.01.05826992838 12Agencia EspaÃ±ola de Medicamentos"/>
 <result pre="version 6)2020117Available from: http://www.gov.cn/zhengce/zhengceku/2020-02/19/content_5480948.htm 11MarmorM.F.KellnerU.LaiT.Y.Y.MellesR.B.MielerW.F.LumF.Recommendations on screening for chloroquine and" exact="hydroxychloroquine" post="retinopathy (2016 revision)Ophthalmology12320161386139410.1016/j.ophtha.2016.01.05826992838 12Agencia EspaÃ±ola de Medicamentos y Productos"/>
 <result pre="(2016 revision)Ophthalmology12320161386139410.1016/j.ophtha.2016.01.05826992838 12Agencia EspaÃ±ola de Medicamentos y Productos SanitariosFicha tÃ©cnica" exact="Hidroxicloroquina" post="Ratiopharm 200Â mgOctubre 201111110.1017/CBO9781107415324.004 13GautretP.LagierJ.-C.ParolaP.HoangV.T.MeddebL.MailheM.Hydroxychloroquine and azithromycin as a"/>
 <result pre="Productos SanitariosFicha tÃ©cnica Hidroxicloroquina Ratiopharm 200Â mgOctubre 201111110.1017/CBO9781107415324.004 13GautretP.LagierJ.-C.ParolaP.HoangV.T.MeddebL.MailheM.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
 <result pre="Antimicrob. Agents202010594910.1016/j.ijantimicag.2020.10594932205204 14GautretP.LagierJ.-C.ParolaP.HoangV.T.MeddebL.SevestreJ.Clinical and microbiological effect of a combination of" exact="hydroxychloroquine" post="and azithromycin in 80 COVID-19 patients with at least"/>
 <result pre="14GautretP.LagierJ.-C.ParolaP.HoangV.T.MeddebL.SevestreJ.Clinical and microbiological effect of a combination of hydroxychloroquine and" exact="azithromycin" post="in 80 COVID-19 patients with at least a six-day"/>
 <result pre="an observational studyTravel Med Infect Dis2020Available from: https://www.groupedeveillecovid.fr/blog/2020/03/28/clinical-and-microbiological-effect-of-a-combination-of-hydroxychloroquine-and-azithromycin-in-80-covid-19-patients-with-at-least-a-six-day-follow-up-an-observational-study/ 15ChenZ.HuJ.ZhangZ.Z.JiangS.HanS.YanD.Efficacy of" exact="hydroxychloroquine" post="in patients with COVID-19: results of a randomized clinical"/>
 <result pre="Wuhan, China: a retrospective cohort studyLancet39520201054106210.1016/s0140-6736(20)30566-332171076 17ChenJ.LiuD.LiuL.A pilot study of" exact="hydroxychloroquine" post="in treatment of patients with common coronavirus disease-19 (COVID-19)J"/>
 <result pre="(COVID-19)J Zhehiang Univ492020Available from: http://www.zjujournals.com/med 18MahaseE.Covid-19: six million doses of" exact="hydroxychloroquine" post="donated to US despite lack of evidenceBMJ3682020m116610.1136/bmj.m116632205321 19Centers for"/>
 <result pre="EvidÃ¨ncia Actual de lâ€™ EficÃ cia i Seguretat de La" exact="Hidroxicloroquina" post="i lâ€™ Azitromicina Com a Tractament o PrevenciÃ³ de"/>
 <result pre="lâ€™ EficÃ cia i Seguretat de La Hidroxicloroquina i lâ€™" exact="Azitromicina" post="Com a Tractament o PrevenciÃ³ de La COVID-192020 23Observational"/>
</results>
